Loading clinical trials...
Loading clinical trials...
A 6-month Prospective, Randomized, Double-blind, Placebo-controlled Clinical Trial Investigating the Efficacy, Safety, and Tolerability of Two Different Doses of Buntanetap or Placebo in Patients With Early Parkinson's Disease
Conditions
Interventions
buntanetap/posiphen
Placebo
Locations
69
United States
University of Alabama at Birmingham (UAB)- The Kirklin Clinic
Birmingham, Alabama, United States
Banner Sun Health Research Institute - Cleo Roberts Center for Clinical Research
Sun City, Arizona, United States
Parkinson's & Movement Disorder Institue (PMDI) - Orange County Office
Fountain Valley, California, United States
UCSF Medical Center - Parkinson's Disease and Movement Disorders Clinic
San Francisco, California, United States
Rocky Mountain Movement Disorder Center
Englewood, Colorado, United States
Ki Health Partners LLC D/B/A New England Institute for Clinical Research
Stamford, Connecticut, United States
Start Date
August 3, 2022
Primary Completion Date
December 4, 2023
Completion Date
December 4, 2023
Last Updated
March 3, 2025
Lead Sponsor
Annovis Bio Inc.
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions